NASDAQ$HROW
Harrow Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported record revenues with a 50% increase over the prior year, driven by branded pharmaceutical products, particularly IHEEZO, but experienced mixed operational performance with some areas underperforming.
Harrow announced record revenues for Q3 2023, a 50% increase year-over-year, driven by strong performance from branded pharmaceutical products, especially IHEEZO. However, the quarter had mixed operational results, with some areas underperforming. The company has adjusted its 2023 financial guidance to revenues of $129 million to $136 million and Adjusted EBITDA of $36 million to $41 million.
- Record revenues were achieved, marking a 50% increase compared to the previous year.
- Branded pharmaceutical products (BPPS) primarily drove the revenue increase, with IHEEZO exceeding internal expectations.
- Strategic amendments to the IHEEZO launch led to a substantial increase in unit demand in September, which continued into the fourth quarter.
- The company adjusted its previously issued 2023 financial guidance to revenues of $129 million to $136 million and Adjusted EBITDA of $36 million to $41 million.
Headline financials
Revenue & EPS history
Harrow · Revenue · Quarterly
$34.3M
Forward guidance
Harrow expects revenues of more than $180 million in 2024, excluding contributions from TRIESENCE.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+1.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+8.3%
Avg return
30 days after
52%
25 / 48 earnings
Positive
+49.3%
Q2 2024
Best reaction
-36.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -18.5% | -6.3% | |
| Q4 2025 | +2.3% | -32.2% | -34.1% | |
| Q3 2025 | +13.6% | +19.5% | +49.7% | |
| Q1 2025 | +3.4% | +6.5% | +25.4% | |
| Q4 2024 | -6.0% | +21.8% | +2.9% | |
| Q3 2024 | -14.1% | -23.9% | -28.9% | |
| Q2 2024 | +49.3% | +56.3% | +67.2% | |
| Q1 2024 | +40.0% | +44.5% | +57.3% | |
| Q4 2023 | +0.3% | +9.6% | +3.4% | |
| Q3 2023 | -36.0% | -30.2% | -21.7% | |
| Q2 2023 | -17.4% | -14.7% | -26.8% | |
| Q1 2023 | -20.5% | -24.1% | -26.9% | |
| Q4 2022 | +6.7% | +22.9% | +42.6% | |
| Q3 2022 | -4.2% | -9.4% | +10.5% | |
| Q2 2022 | +12.2% | +24.6% | +32.6% | |
| Q1 2022 | +3.3% | -5.3% | +15.3% | |
| Q4 2021 | +3.0% | -1.4% | -1.7% | |
| Q3 2021 | -4.9% | -3.3% | -21.1% | |
| Q2 2021 | -0.3% | -0.8% | +13.0% | |
| Q1 2021 | +15.8% | +14.5% | +14.0% | |
| Q4 2020 | +3.5% | +3.4% | -12.3% | |
| Q3 2020 | +25.8% | +30.0% | +19.9% | |
| Q2 2020 | +4.8% | +10.4% | +15.0% | |
| Q1 2020 | -5.8% | -9.7% | +36.5% | |
| Q4 2019 | -7.5% | -16.0% | -3.8% | |
| Q3 2019 | +18.6% | +16.1% | +33.8% | |
| Q2 2019 | -23.6% | -21.7% | -8.0% | |
| Q1 2019 | +10.1% | +16.5% | +26.6% | |
| Q4 2018 | -7.5% | -20.3% | -30.1% | |
| Q3 2018 | +7.2% | +23.0% | +38.4% | |
| Q2 2018 | +13.4% | +29.3% | +26.4% | |
| Q1 2018 | +9.3% | +5.3% | +6.2% | |
| Q4 2017 | -3.4% | -5.3% | -3.9% | |
| Q3 2017 | +5.7% | +19.1% | +7.6% | |
| Q2 2017 | -7.9% | -9.7% | -28.2% | |
| Q1 2017 | -4.8% | -12.6% | -22.5% | |
| Q4 2016 | +2.9% | +17.0% | +79.7% | |
| Q3 2016 | -9.8% | -13.2% | -28.9% | |
| Q2 2016 | -3.1% | -2.6% | +6.5% | |
| Q1 2016 | +1.9% | — | — | |
| Q4 2015 | -2.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +3.5% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +7.8% | — | — | |
| Q2 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro